Clinical Trial Update: A Long Term Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia Converted From Erythropoieses Stimulating Agent (ESA) Treatment [Phase 3]

View source ↗

Summary

This document reports the completion of a Phase 3 long-term trial of intermittent oral ASP1517 in hemodialysis patients with anemia due to chronic kidney diseas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia of Chronic Kidney Disease
• Chronic Kidney Disease

Drugs mentioned

• ASP1517

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Hemodialysis Patients With Renal Anemia | Phase 3 | Status: COMPLETED